Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: fracture

Heart Safety Clouds Hopes for Amgen, UCB Bone Drug Approval

Bill Berkrot & Ben Hirschler  |  May 23, 2017

(Reuters)—Amgen Inc. and UCB SA no longer expect their experimental osteoporosis drug to win U.S. approval this year after a higher rate of serious heart-related side effects were observed in a late-stage clinical trial. The drug, romosozumab, which would be sold under the brand name Evenity if approved, is awaiting an approval decision by the…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:FDAFood and Drug AdministrationOsteoporosisromosozumab

Infliximab-abda Becomes 5th Biosimilar Approved in the U.S. & Abaloparatide Approved for Osteoporosis

Michele B. Kaufman, PharmD, BCGP  |  May 22, 2017

The FDA has approved infliximab-abda, a biosimilar for treating multiple rheumatic diseases, as well as abaloparatide for treating postmenopausal women with osteoporosis…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:abaloparatideFDAFood and Drug Administrationinfliximabinfliximab-abdaOsteoporosis

5 Easy-to-Implement Quality Improvement Projects for Rheumatology Practices

Carina Stanton  |  May 16, 2017

Quality assurance and quality improvement (QA/QI) work makes sense to focus on. However, finding the time and resources for QI projects is not always easy. Until now, the business case for QI in rheumatology practice has not always been clear. However, this is changing with implementation of the Medicare Access and CHIP Reauthorization Act (MACRA)…

Filed under:Practice SupportQuality Assurance/Improvement Tagged with:Practice Managementquality assurancerheumatologistrheumatology

Rheumatologists Respond to Prescription Opioid Analgesic Crisis

Larry Beresford  |  May 16, 2017

The alarming statistics on prescription opioid overdoses are well known to medical professionals, thanks to the Centers for Disease Control and Prevention (CDC)’s widely cited finding that deaths from opioid analgesics have increased fourfold since 1999.1 Half of all fatal drug overdoses now involve opioids prescribed by a doctor. Meanwhile, a lack of rigorous research…

Filed under:AnalgesicsConditionsDrug UpdatesPain SyndromesPractice Support Tagged with:AddictionanalgesicChronic painepidemicManagementopioidOverdosepatient careprescriptionRheumatic DiseaserheumatologistrheumatologyriskSafetyTreatment

MicroRNAs Provide Insight into Bone Metabolism

Lara C. Pullen, PhD  |  May 1, 2017

A recent study examined the functional variants within microRNAs that affect bone metabolism and possibly bone disorders. Researchers found overexpression of microRNAs may contribute to the osteoporotic phenotype, and the gene targets associated with two specific osteoblast-expressed microRNAs may be critical in osteoporosis…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:bonemicroRNAOsteoporosisRNAsingle nucleotide polymorphisms

Studies Highlight Risk of Damage from Lupus Treatments

Mary Beth Nierengarten  |  April 20, 2017

WASHINGTON, D.C.—Conference goers who braved the final day of the 2016 ACR/ARHP Annual Meeting were awarded for their stamina by learning about issues relating to the damage caused by systemic lupus erythematosus (SLE) during the session Systemic Lupus Erythematosus—Clinical Aspects and Treatment V: Damage and Morbidity. Minimizing Damage: Early Use of GC-Sparing Strategies Jayne Little,…

Filed under:ConditionsMeeting ReportsResearch RheumSystemic Lupus Erythematosus Tagged with:2016 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)damageglucocorticoidLupusmorbiditymortalitypatient careResearchrheumatologySLEtherapyTreatment

Diagnosis of Acute Gouty Arthritis Obscured by Anchoring Bias

Diagnosis of Acute Gouty Arthritis Obscured by Anchoring Bias

Sneha Patel, MD, Monica Mohile, MD, & Arundathi Jayatilleke, MD  |  April 19, 2017

A 56-year-old African American man presents to the emergency department with polyarthralgias and a fever of 103ºF. One month prior to admission, he presented with right knee pain and swelling. Blood cultures grew S. epidermidis. He was treated for presumed septic arthritis complicated by MSSE bacteremia. He was treated with meropenem and a prolonged course…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:anchoring biasArthritiscase reportClinicalDiagnosisdiagnostic testingGoutinflammationjointoutcomepatient carepolyarthralgiaRArheumatologistrheumatologyseropositive rheumatoid arthritisTreatment

Insufficient Evidence Regarding Osteoporosis Medications in Kidney Patients

Will Boggs, MD  |  April 11, 2017

NEW YORK (Reuters Health)—There are insufficient data to make evidence-based decisions regarding the benefits and harms of osteoporosis medications in patients with chronic kidney disease (CKD), according to a systematic review and meta-analysis. “We found low to moderate evidence for the effects of some but not all of the medications, and the evidence was limited…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:biophosphonatesbone mineral density (BMD)chronic kidney diseasedenosumabkidneyOsteoporosisosteoporosis treatments

U.S. & Europe Evaluate Abaloparatide Injection & Europe Approves Marketing Baricitinib for RA

Michele B. Kaufman, PharmD, BCGP  |  April 11, 2017

Injectable abaloparatide is being evaluated in the U.S. and Europe to treat postmenopausal women with osteoporosis…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:abaloparatidebaricitinibJanus Kinase InhibitorsOsteoporosispostmenopauseWomen

Alterations in the Microbiome Are Associated with Changes in Bone Quality

Lara C. Pullen, PhD  |  March 28, 2017

By treating mice with antibiotics, researchers found that alterations in the gut microbiome impaired the mechanical properties of bone and depleted splenic B and T cell populations. The researchers suspect the decrease in bone strength resulted from the change in the immune system…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:bonebone mineral density (BMD)gut microbiomeMicrobiomeOsteoporosis

  • « Previous Page
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • …
  • 43
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences